Login to Your Account

Schizophrenia, Alzheimer's Trials Ongoing

Another Miss for Targacept; TC-5619 Fails in ADHD Trial

By Jennifer Boggs
Managing Editor

Tuesday, September 18, 2012
Targacept Inc.'s TC-5619 missed its endpoint in a Phase II study in inattentive-predominant attention deficit hyperactivity disorder (iADHD), the latest in a string of disappointing news for its neuronal nicotinic receptor (NNR) pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription